PT Millennium Pharmacon International Tbk (ISX:SDPC) YoY EBITDA Growth: 25.24% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:SDPC PT Millennium Pharmacon International Tbk ISX:SDPC
79 GF Score
Price Rp208.00
GF Value Rp170.76
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is PT Millennium Pharmacon International Tbk YoY EBITDA Growth?

PT Millennium Pharmacon International Tbk ISX:SDPC +4.52% 79 YoY EBITDA Growth is 25.24% as of Jun. 2026. GuruFocus rates ISX:SDPC with a GF Score™ of 79/100 and a GF Value™ of Rp170.76 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. PT Millennium Pharmacon International Tbk's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 25.24%.

PT Millennium Pharmacon International Tbk's EBITDA per Share for the three months ended in Jun. 2026 was Rp29.25.

PT Millennium Pharmacon International Tbk YoY EBITDA Growth Related Terms

PT Millennium Pharmacon International Tbk YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for PT Millennium Pharmacon International Tbk's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Millennium Pharmacon International Tbk YoY EBITDA Growth Chart

PT Millennium Pharmacon International Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.70 24.28 36.11 -3.57 14.30

PT Millennium Pharmacon International Tbk Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.61 -3.25 74.57 -9.60 25.24
ISX:SDPC
79GF Score
PT Millennium Pharmacon International Tbk ISX:SDPC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Millennium Pharmacon International Tbk YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

PT Millennium Pharmacon International Tbk's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(107.714-94.242)/ | 94.242 |
=14.30 %

PT Millennium Pharmacon International Tbk's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(29.25-23.355)/ | 23.355 |
=25.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 25.24% mean?
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a YoY EBITDA Growth of 25.24% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for PT Millennium Pharmacon International Tbk and its competitors.
Is PT Millennium Pharmacon International Tbk's YoY EBITDA Growth too high?
PT Millennium Pharmacon International Tbk's current YoY EBITDA Growth is 25.24%. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's YoY EBITDA Growth compare to MCK and COR?
PT Millennium Pharmacon International Tbk's YoY EBITDA Growth of 25.24% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Distribution company?
A good YoY EBITDA Growth depends on the Medical Distribution industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for PT Millennium Pharmacon International Tbk and its competitors. PT Millennium Pharmacon International Tbk's current YoY EBITDA Growth is 25.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp170.76, compared to a current price of Rp208.00 — trading 21.8% above its estimated fair value. The current YoY EBITDA Growth is 25.24%. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current YoY EBITDA Growth is 25.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?

Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued. The current stock price of Rp208.00 is trading 21.8% above its estimated GF Value™ of Rp170.76. GuruFocus considers PT Millennium Pharmacon International Tbk to be Modestly Overvalued.

Key valuation signals for ISX:SDPC:

  • YoY EBITDA Growth: 25.24%
  • GF Value™: Rp170.76 vs. price of Rp208.00 (21.8% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Millennium Pharmacon International Tbk Business Description

Address Jl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score

Get the complete analysis for ISX:SDPC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp208.00
Price
Rp170.76
GF Value